Furthermore, in a recent update on the phase 3 ADJUVANT BR.31 trial, adjuvant durvalumab failed to achieve a statistically significant improvement in DFS compared to placebo in patients with resected stage IB–IIIA EGFR and ALK wild-type NSCLC and with a PD-L1 expression ≥25% [75]. This evidence concerns the gene ALK and non-small cell lung carcinoma.